0001209191-23-012315.txt : 20230223
0001209191-23-012315.hdr.sgml : 20230223
20230223174048
ACCESSION NUMBER: 0001209191-23-012315
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230217
FILED AS OF DATE: 20230223
DATE AS OF CHANGE: 20230223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Crockett Thomas Andrew
CENTRAL INDEX KEY: 0001690920
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 23661256
MAIL ADDRESS:
STREET 1: BUILDING 227, TETRICUS SCIENCE PARK
STREET 2: PORTON DOWN, SALISBURY
CITY: WILTSHIRE
STATE: X0
ZIP: SP4 0JQ
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200915291
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (857) 999-0075
MAIL ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Therapeutics, Inc.
DATE OF NAME CHANGE: 20140916
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-17
0
0001348911
KalVista Pharmaceuticals, Inc.
KALV
0001690920
Crockett Thomas Andrew
C/O KALVISTA PHARMACEUTICALS, INC.
55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE
MA
02142
1
1
0
0
CEO
Common Stock
2023-02-17
4
M
0
12749
A
127627
D
Common Stock
2023-02-17
4
S
0
6700
7.66
D
120927
D
Performance Restricted Stock Unit
2023-02-17
4
M
0
6944
0.00
A
Common Stock
6944
0
D
Restricted Stock Unit
2023-02-17
4
M
0
5805
0.00
D
Common Stock
5805
75465
D
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Shares earned upon the vesting of a percentage of the performance restricted stock units ("PRSUs") granted to the Reporting Person on January 11, 2023. Each PRSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Data and Enrollment Metrics goals ("Performance Metrics"). 1/12th of the total number of shares subject to the PSRU shall vest on each quarterly anniversary of the Vesting Commencement Date of November 17, 2022, upon Performance Metrics achieved, subject to continued service through each vesting date.
1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.
/s/ Benjamin L. Palleiko, Attorney-in-Fact
2023-02-23